Trastuzumab Suppliers & Bulk Manufacturers
Available Forms: IV & SQ Injection
Available Strengths: IV : 150 mg/ 7.5 mL (vial); SQ: 600 mg/ 5 mL (syringe)
Reference Brands: Herceptin® (EU & US); Herceptin Hylecta® (subcutaneous formulation)
Category:
Oncology Cancer Care
Trastuzumab (Herceptin®) is a monoclonal antibody used to treat HER2-positive breast and gastric cancer. It targets the HER2 receptor, inhibiting cancer cell growth. Available in intravenous (IV) and subcutaneous (SC) formulations, it comes in 150 mg vials (IV) and 600 mg syringes (SC). Widely used in combination therapy, it improves outcomes for HER2-positive cancers in both the US and EU.
Trastuzumab is available in IV & SQ Injection
and strengths such as IV : 150 mg/ 7.5 mL (vial); SQ: 600 mg/ 5 mL (syringe).
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Trastuzumab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Trastuzumab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Trastuzumab is a monoclonal antibody used in oncology, primarily for the treatment of HER2-positive breast cancer and gastric cancer. It works by targeting the HER2 receptor, a protein that is overexpressed in some cancer cells, blocking its signaling and inhibiting cancer cell growth. Available as Herceptin® in both the US and EU, Trastuzumab is offered in intravenous (IV) and subcutaneous (SC) formulations. The IV formulation is commonly administered in 150 mg vials, while the SC formulation is available in 600 mg syringes. Used as part of combination therapy, it improves patient outcomes in HER2-positive cancers.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing